Comparison of 10-year atherosclerotic cardiovascular disease (ASCVD) risk in metropolitan and rural areas of South of Iran.

The first step to reducing the growing burden of cardiovascular disease (CVD) is to find modifiable risk factors with the highest burden in each population. Urban and rural citizens may have different priorities in this regard. This study aimed to compare the 10-year incidence probability of CVD events and its associated risk factors between rural and urban areas in Iran.

The association between low carbohydrate dietary score (LCDS) and cardiovascular risk factors: results from the Shiraz Heart Study (SHS).

Background: Cardiovascular disease (CVD) is a major cause of death and recent studies have highlighted the potential role of dietary carbohydrate indices in cardiovascular health. Given the controversial results in this field, the aim of this study was to investigate the association between low carbohydrate dietary score (LCDS) and CVD risk factors in a population of Iranian adults.

Methods: This cross-sectional study was conducted within the framework of the Shiraz Heart Study (SHS) including 1982 adults.

Association of Dietary Patterns with Metabolic Syndrome among Middle-Aged Adults in Shiraz, Iran: Shiraz Heart Study (SHS).

Introduction: Metabolic syndrome (MetS) is a noncommunicable disease with a high burden, including the development of type 2 diabetes mellitus, cardiovascular events, and death. It is characterized by abdominal obesity, elevated blood pressure, increased fasting plasma glucose levels, hypertriglyceridemia, and reduced levels of high-density lipoprotein (HDL) cholesterol. MetS is preventable by modifying lifestyle and dietary patterns, which are major contributing factors.

Design and rationale for a randomized, open-label, parallel clinical trial evaluating major adverse cardiovascular events (pharmacological treatment versus diet control) in patients with high-normal blood pressure: the PRINT-TAHA9 trial.

Background: The distinction between normal and high blood pressure remains a debated topic, with varying guidelines on when to start medication. Contemporary guidelines advocate for the initiation of antihypertensive therapy in individuals who present with high-normal blood pressure, particularly those exhibiting elevated 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores. Despite these recommendations, there is a notable lack of direct evidence supporting the efficacy of treating high-normal blood pressure to prevent major adverse cardiovascular events (MACE).